Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that's working with Gilead's Kite unit.
Shoreline CEO Kleanthis Xanthopoulos confirmed the workforce reduction on ...
↧
